Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)
Bile Duct Diseases, Biliary Tract Diseases, Gallbladder Diseases
About this trial
This is an interventional prevention trial for Bile Duct Diseases
Eligibility Criteria
Inclusion criteria: Adults weighing up to 125 kg who are undergoing ERCP for any of the following: Evaluate recurrent abdominal pain; Evaluate unexplained recurrent pancreatitis; Evaluate prior post-ERCP pancreatitis; Treatment of pancreatic disorders; Treatment of Common Bile Duct Stones (without jaundice) Exclusion criteria: Active (acute) pancreatitis; Chronic pancreatitis (moderate and severe cases); ERCP to perform a second procedure on biliary tract; Patients who previously had pancreatic sphincterotomy; Known or suspected pancreatic cancer or cancer of Papilla of Vater; Known or suspected other malignancy; History of, or current clotting or bleeding problems; Moderate and severe Anemia; Low platelet counts